Shareholder notification

RNS Number : 7406B

Venn Life Sciences Holdings PLC

20 June 2016

 

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Shareholder notification

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology and medical device clients, has been informed today that Mr David Newton no longer holds a notifiable shareholding in the Company.

Enquiries:

Venn Life Sciences Holdings Plc		www.vennlifesciences.com
Tony Richardson, Chief Executive Officer		Tel: [phone]
Jonathan Hartshorn, Chief Financial Officer		Tel: [phone]
Aoife O Farrell, Marketing Manager		Tel: [phone]
Davy (Nominated Adviser, ESM Adviser and Joint Broker)		Tel: [phone]
Fergal Meegan / Matthew DeVere White (Corporate Finance)
Paul Burke (Corporate Broking)
Hybridan LLP (Joint-Broker)
Claire Louise Noyce		Tel: [phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus		Mob: [phone]
Lianne Cawthorne		Mob: [phone]

About Venn Life Sciences Limited: Venn Life Sciences is a Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn Life Sciences specialises in rapid deployment and management of multisite projects, across all phases. Venn Life Sciences also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.

For more information about the Company, please visit: www.vennlifesciences.com

 

END

 

 

DSHAKKDDPBKDFAB